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Abstract
One important function of endothelial cells in glioblastoma multiforme (GBM) is to create a niche that helps
promote self-renewal of cancer stem-like cells (CSLC). However, the underlying molecular mechanism for this
endothelial function is not known. Since activation of NOTCH signaling has been found to be required for
propagation of GBM CSLCs, we hypothesized that the GBM endothelium may provide the source of NOTCH
ligands. Here, we report a corroboration of this concept with a demonstration that NOTCH ligands are expressed
in endothelial cells adjacent to NESTIN and NOTCH receptor-positive cancer cells in primary GBMs. Coculturing
human brain microvascular endothelial cells (hBMEC) or NOTCH ligand with GBM neurospheres promoted
GBM cell growth and increased CSLC self-renewal. Notably, RNAi-mediated knockdown of NOTCH ligands in
hBMECs abrogated their ability to induce CSLC self-renewal and GBM tumor growth, both in vitro and in vivo.
Thus, our findings establish that NOTCH activation in GBM CSLCs is driven by juxtacrine signaling between
tumor cells and their surrounding endothelial cells in the tumor microenvironment, suggesting that targeting
both CSLCs and their niche may provide a novel strategy to deplete CSLCs and improve GBM treatment.
Cancer Res; 71(18); 6061–72. 2011 AACR.
Introduction
Glioblastoma multiforme (GBM) is the most lethal malig-
nant brain tumor in adults without revolutionary improve-
ment in treatment during the past 30 years (1, 2). Any
treatment that can significantly prolong patients’ overall
survival for more than 3 months, which is the best achieve-
ment so far to treat GBM when using surgery, radiation
therapy, and temozolomide, can be considered as a success
(3). Emerging evidence shows that a small population of
cancer stem-like cells (CSLC) within neoplasms is responsible
for tumor propagation (4), including GBM (5, 6). Therapies
targeting CSLCs bring hope for brain tumor patients (7–10).
We have shown that activation of the NOTCH pathway in
GBMCSLC is required for their growth in vitro and in vivo (10).
However, the molecular mechanism by which NOTCH is
activated in GBM CSLCs and if CSLCs, like their normal
cognates, also need a niche to self-renew is unclear.
The stem cell niche is a microenvironment where stem cells
reside. It is composed of stem cells, neighboring supportive
cells, extracellular matrix, and other factors required for stem
cell self-renewal (11). In the CNS, neural stem cells (NSC) are
located at the subventricular zone (SVZ) of the lateral ventricle
and subgranular zone of the dentate gyrus in the hippocampus
(12–14). Some astrocytes and neuroblasts and endothelial
cells in the SVZ are thought to contribute to these NSC niches
by providing growth factors or membrane-bound ligands to
NSCs for self-renewal (15). Although normal stem cells need
to reside within a niche to self-renew (11), what a CSLC niche is
composed of is largely unknown. As CSLCs sharemany proper-
ties with normal stem cells, CSLCsmay also need a CSLC niche
to self-renew. A recent report showed that endothelial cells
function as a CSLC niche to promote CD133þ CSLC self-
renewal inmedulloblastoma andGBM (16). However, signaling
pathways regulating the CSLC niche are still unclear.
The Notch locus was first described by Morgan in a strain of
Drosophila with notched wing blades (17). Seventy years later,
the gene was cloned as a cell surface receptor (18) playing a
key role in the development of many different cell types and
tissues, including neuron and glia (19–22). NOTCH signaling is
initiated when transmembrane ligands on one cell bind
NOTCH receptors on an adjacent cell and cause a gamma
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secretase-mediated proteolytic release of the NOTCH intra-
cellular domain (NICD) (23). NICD then translocates into the
nucleus where it interacts with the transcriptional cofactor
CBF1 and activates targets such as the HES and HEY genes to
modulate cell fate (20, 21). In vertebrates, 4 NOTCH receptors
(NOTCH 1-4), 5 ligands (JAGGED1,2, DLL1,3,4), and multiple
effector molecules (HES1-6, HEY1,2,L) have been identified
(24). During normal development, ligand expressing cells
(signal-sending cell) generally have reduced NOTCH activity,
whereas NOTCH receptor-expressing cells (signal-receiving
cell) have elevated NOTCH activity (25). In general, signal-
sending cells will undergo differentiation, whereas signal-
receiving cells remain in an undifferentiated state (stem cell
state). This phenomenon is called "lateral specification" (Sup-
plementary Fig. S1; ref. 25). We and others have recently
shown that GBM CSLCs have elevated NOTCH activity (10,
26, 27), and that NOTCH pathway blockade with a gamma-
secretase inhibitor depletes GBM CSLCs, inhibits tumor
growth, and prolongs survival of mice bearing intracranial
xenografts (10). In this study, we investigated whether
acquired NOTCH activity in GBMCSLCs comes from endothe-
lial cells, which function as niche cells to promote GBM CSLC
self-renewal by providing NOTCH ligands to NOTCH recep-
tors expressed in GBM CSLCs.
Materials and Methods
GBM samples
Fresh primary GBM samples were obtained from the Uni-
versity of Michigan Hospitals with approval from the Internal
Review Board.
Cell culture
Given the evidence that only someGBMcells fall in the CSLC
hypothesis (28), we only choose GBM neurospheres that we
have shown to fall in the CSLChypothesis for this study (10, 29).
GBM neurosphere cells (HSR-GBM1, HSR-GBM2, and HSR-
GBM3) derived from 3 different GBM patients were cultured
and maintained in NeuroCult proliferation medium (STEM-
CELL Technologies) supplemented with 10 ng/mL epidermal
growth factor (EGF; PeproTech), 10 ng/mL FGFb (PeproTech),
and 2 mg/mL heparin (Sigma; ref. 10). Human brain micro-
vascular endothelial cells (hBMEC) and human umbilical vein
endothelial cells (HUVEC) were purchased from Cell Systems
Corporation (catalogue #ACBRI-376) and ATCC (catalogue
#CRL-1730), respectively. hBMECs were maintained in CSC
complete medium (Cell Systems) and HUVECs were cultured
in F12K with 10% FBS, 0.1 mg/mL heparin, and 0.03 mg/mL
endothelial cell growth supplement. For coculture system,
neurospheres were seeded on top of the attached endothelial
cells andmaintained in the serum-free endothelial cellmedium
(Invitrogen) supplemented with 10 ng/mL EGF, 20 ng/mL
FGFb, and 10 mg/mL heparin. For GBM cell differentiation,
plates were coated with 15 ug/mL polyornithine for a mini-
mum of 3 hours at 37C. GBM cells were then cultured on the
coated plates at the density of 1  105 cells/cm2 in NeuroCult
differentiation medium (STEMCELL Technology). The differ-
entiated GBM cells were utilized 7 to 14 days later.
Lentivirus production and shRNA transduction
Lentiviruses were produced by transfecting BOSC 23 cells
(ATCC, catalogue #CRL-11270) with 16 mg total of pSicoR
(Addgene, catalogue #11579), psPAX2 (Addgene, catalogue
#12260), and PMD.2G (Addgene, catalogue #12259) plasmids
with a ratio of 5: 3.5: 1.75 in a 10-cm dish, using lipofectamine
2000 (Invitrogen; ref. 30). Tranfected cell media containing
viruses were collected 48 hours later and filtered through a
0.45-mm polyvinylidene difluoride membrane. Virus-contain-
ing media were used immediately or stored at 80C. Cells
were transduced with lentiviruses by the centrifugation
method (1,000  g, 1.5 hours) with addition of 4 to 8 mg/
mL polybrene. The medium was changed the next day, and
gene expression was analyzed 1 week later (31). Transduction
efficiency was monitored by green fluorescent protein (GFP)
intensity with greater than 90% of cells being infected (30).
shRNA sequences were designed by pSicoOligomaker 1.5
(courtesy of Dr. T. Jacks, MIT). The siRNA sequences used
to knock down NOTCH ligands were 50-GTGAGTGGTTGAA-
TATGAT-30 for JAG1 and 50-GGAGAGAGGGGGCCAATGA-30
for DLL4.
Orthotopic xenograft implantation
Mice were obtained and experiments were done in accor-
dance with guidelines from the University Animal Care and
Use Committee at the University of Michigan. Four to 5 week-
old athymic nude-Foxn1nu mice were purchased from Harland
Laboratories for intracranial xenograft implantation (8, 10). A
total of 50,000 single cells from GBM neurospheres with or
without 50,000 endothelial cells were stereotactically injected
into the brain (2 mm right, 1 mm back, 2 mm deep from the
bregma; refs. 8, 10). Tumor growth was monitored by MRI
(Supplementary Methods).
Statistical analysis
Statistical analyses were done using GraphPad Prism 4
(GraphPad Software). Data graphed with error bars represent
mean and SE from experiments done in triplicate unless
otherwise noted. A 2-sided Student's t test was used to
determine the significance of any differences.
Results
NOTCH receptor-expressing cells are colocalized with
NESTIN-positive tumor cells in primary GBM and have
elevated level of NOTCH activity
Recently, we have shown that Notch pathway blockade
depletes GBM CSLCs in vitro and prevents their propagation
in vivo (10). To investigate whether NOTCH receptor-expres-
sing cells in primary GBMs are CSLCs, we first examined
NOTCH1 and NESTIN expression by immunofluorescence
staining in primary GBM frozen sections. We found that
NOTCH1-expressing cells colocalized with NESTIN-expres-
sing cells in 3 different primary GBM samples (Fig. 1A).
NOTCH2-expressing cells also colocalized with NESTIN-
expressing cells in primary GBMs (Supplementary Fig. S2).
Furthermore, NOTCH ligand JAG1- or DLL1-expressing cells
are adjacent to the cells with NOTCH pathway activation as
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indicated by HES5 expression (Fig. 1B). In addition, HES5-
expressing cells are colocalized with NOTCH1- and NOTCH2-
expressing cells in primary GBMs (Fig. 1C). These results
suggest that the NESTIN-positive GBMCSLCs express NOTCH
receptors and show elevated level of NOTCH activity. These
data indicate that NOTCH ligand-expressing cells within the
tumor may function as a CSLC niche by providing ligands to
NOTCH receptors expressed in GBM CSLCs to activate the
NOTCH pathway in CSLCs and to promote CSLC self-renewal,
replicating the lateral specification phenomenon seen in
normal tissue development (Supplementary Fig. S1).
NOTCH ligands are expressed in the endothelial cells
surrounded by tumor cells in primary GBMs
Next, we sought to identify the nature of NOTCH ligand-
expressing cells within GBM. First, we examined NOTCH
ligands DLL1, DLL4, JAG1, and JAG2 expression in frozen
sections of primary GBM samples using immunofluorescence.
We found that DLL1 is expressed in most tumor cells, whereas
DLL4 is exclusively expressed in endothelial cells (CD31þ)
within GBM (Fig. 2A). JAG1 or JAG2 is expressed in both
endothelial cells and some tumor cells (Fig. 2A and data not
shown). Interestingly, using Western blot we found that cells
from GBM neurosphere line HSR-GBM1 also expressed DLL1
and JAG1, but not DLL4 (Fig. 2C). hBMECs expressed DLL4
and JAG1, but no detectable DLL1 (Fig. 2C). A second type of
endothelial cell, HUVEC, also expressed JAG1 and DLL4, but
not DLL1 (data not shown). The expression pattern of these
NOTCH ligands detected by Western blot is consistent with
our findings in primary GBMs by immunofluorescence
(Fig. 2A). Furthermore, the NOTCH1 receptor and a CSLC
marker, NESTIN, are expressed in the tumor cells adjacent to
JAG1-expressing endothelial cells or tumor cells (Fig. 2B),
recapitulating the "lateral inhibition" pattern of cell distribu-
tion commonly seen in NOTCH-regulated normal develop-
ment (Supplementary Fig. S1; ref. 25). Taken together, these
data suggest that endothelial cells within GBM may function
as a CSLC niche by providing NOTCH ligands to NOTCH
receptors expressed in CSLCs to activate the NOTCH pathway
in CSLCs.
Better differentiated GBM cells express higher level of
NOTCH ligands and reduced level of CD133 and are less
tumorigenic in mouse
The fact that NOTCH ligand JAG1 is expressed in tumor
cells adjacent to the NOTCH receptor- and NESTIN-expres-
Figure 1. NOTCH receptor-
expressing cells are colocalized
with NESTIN-positive tumor cells
in primary GBM and have elevated
level of NOTCH activity adjacent
to NOTCH ligand-expressing
cells. A, expression of NOTCH1
and NESTIN was colocalized in
the same cells in the primary GBM
tumors (GBM-071409, GBM-
032410, and GBM-022610). B,
JAG1-expressing cells or DLL1-
expressing cells (green,
arrowhead) were adjacent to
HES5-expressing cells (red,
arrow) in primary GBM samples.
C, NOTCH1- or NOTCH2-
expressing cells were colocalized
with HES5-expressing cells
(arrow) in primary GBM samples.
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sing cells in primary GBMs (Fig. 2B) indicates some tumor
cells may also function as a stem cell niche to provide NOTCH
ligands to NOTCH receptors expressed in adjacent CSLCs. To
test this, we first forced GBM neurosphere to differentiate,
grow as mono-layer, and attach to the culture plate by switch-
ing to the differentiation medium. We found that the pro-
liferation rate detected by Ki-67 staining was reduced and 3
lineage differentiation markers GFAP (glia), Tuj1 (neuron),
and Gal-C (oligodendrocyte) were induced in the differen-
tiated GBM cells (Fig. 3A). GFAP-positive cells were increased
from 84.7  4.8% to 95.9  1.3%, Tuj-1-positive cells from 20.5
 6.1% to 88.6 1.8%, and Gal-C-positive cells from 0 to 1.5
0.9% (P < 0.01, t test). Expression of DLL1 was also induced in
the differentiated cells (Fig. 3B). Furthermore, DLL1 is upre-
gulated in all neurosphere lines HSR-GBM1-3 (Fig. 3B, Sup-
plementary Fig. S3). Interestingly, HSR-GBM2 showed
upregulation of all the ligands (Supplementary Fig. S3). In
addition, expression of CSLC marker CD133 and NOTCH
target HES1 were reduced in differentiated GBM cells
(Fig. 3B), suggesting that GBM CSLCs lose NOTCH activity
and "stemness" when they are differentiated. Consistent with
these data, CD133-positive population was reduced in differ-
entiated GBM cells (Fig. 3C). The CD133-negative GBM popu-
lation also had elevated levels of NOTCH ligand DLL1
expression compared with the CD133-positive population
(Fig. 3C). Finally, when we injected 50,000 neurosphere cells
or 50,000 differentiated GBM cells into the forebrain of
immunodeficient mice, 100% (5 of 5) of mice receiving
GBM neurosphere cells formed large intracranial xenografts
as detected by MRI (Fig. 3D), whereas only 40% (2 of 5) of mice
injected with differentiated GBM cells formed tumors. Brain
pathology confirmed the existence of intracranial xenografts
and formation of larger tumor in the neurosphere-derived
xenografts (Fig. 3D). GBM intracranial xenograft also shows a
similar feature as human primary tumor (Supplementary
Fig. S4). These data show that GBM neurospheres enrich
tumor-initiating CSLCs and that they can be used as a
CSLC-enrichment model whereas forced differentiated cells
can be used as a CSLC-depletion model, consistent with
previous reports (6, 8, 29). Taken together, these data suggest
that GBM neurospheres enrich CSLC population and that
differentiated GBM cells may also provide NOTCH ligands to
NOTCH receptors expressed in adjacent GBM CSLCs.
NOTCH ligands promote GBM neurosphere growth in
vitro
To examine whether NOTCH ligands expressed in endothe-
lial cells and differentiated tumor cells may have functional
effects on GBM cells, we treated GBM neurosphere with
soluble JAG1 or DLL1 peptide and examined GBM neuro-
sphere growth. We found that JAG1 peptide treatment for
5 days increased HSR-GBM1 and HRS-GBM2 neurosphere
growth in a dose-dependent fashion (Fig. 4A). Furthermore,
both JAG1 and DLL1 peptide induced HSR-GBM3 neurosphere
Figure 2. Expression pattern of NOTCH ligands in primary GBMs. A, NOTCH ligand DLL1 (green) was expressed in some GBM cells (arrow) and in some
endothelial cells (CD31þ) around the blood vessels (arrow head). JAG1 was expressed in both tumor cells (arrow) and blood vessels (arrow head).
DLL4 was expressed in the blood vessels and colocalized with CD31 staining in endothelial cells (arrow head). B, NOTCH1 receptor and CSLCmarker NESTIN
were expressed in tumor cells (arrow) adjacent to JAG1-expressing endothelial cells or tumor cells (arrow head). C, Western blots showed expression of JAG1,
DLL1, and DLL4 in GBM neurosphere cells (lane 1 and 2: same GBM cells) and hBMECs (lane 3), consistent with immunohistochemistry results.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control.
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growth in vitro (Fig. 4A), suggesting that NOTCH ligand may
induce NOTCH signaling in CLSCs through being immobilized
by attachment to the extracellular matrix or the adjacent cells
(32, 33). A weak growth response in HSR-GBM3 may be due to
the different genetic/epigenetic backgrounds among different
tumors.
In addition, expression of CSLC marker CD133 and CD15
were also induced in JAG1 or DLL1 peptide-treated GBM
Figure 3. Differentiated GBM cells
express NOTCH ligands and have
reduced ability to form in-
tracranial xenograft in mice. A,
HSR-GBM1 neurosphere line was
forced to differentiate and grow as
a monolayer, which had reduced
proliferation (*, P < 0.05, t test) and
induced expression of GFAP
(glial), Tuj1 (neuronal), and GalC
(oligodendrocyte) markers. B,
differentiated HSR-GBM1 cells
expressed higher levels of DLL1
and GFAP at the mRNA level
detected by quantitative RT-PCR
(left). In addition, differentiated
cells expressed a higher level of
DLL1 and lower levels of NOTCH
target HES1 and stem cell marker
CD133 at the protein level as
detected by Western blot in 2
different GBM neurosphere lines,
HSR-GBM1 and HSR-GBM2. C,
CD133-positive population was
significantly reduced in
differentiated tumor cells
compared with GBM
neurospheres (HSR-GBM1)
detected by flow cytometry (left).
In addition, CD133-negative
population in HSR-GBM1
neurospheres expressed higher
levels of DLL1 and GFAP at mRNA
level compared with CD133-
positive population (middle).
Upregulation of DLL1 in CD133-
negative population was also
confirmed at the protein level by
Western blot (right). D, when GBM
neurospheres or differentiated
cells from HSR-GBM1 labeled
with GFP using lentivirus were
injected into the mouse brain,
neurosphere cells formed large
xenografts as detected by MRI
(dash circle), whereas
differentiated cells had reduced
ability to form xenografts.
Pathology was confirmed by
hematoxylin and eosin (H&E)
staining and immunostaining of
the proliferation marker Ki-67.
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neurospheres (Fig. 4B), suggesting that activation of NOTCH
signaling by JAG1 or DLL1 increases self-renewal of GBM
CSLCs in vitro. Finally, we used clonogenesis as a functional
CSLC marker to examine if hBMECs can induce GBM CSLC
self-renewal. First, we labeled hBMECs with GFP by lentiviral
vector and cocultured hBMECs with unlabeled GBM neuro-
spheres (Fig. 4C) for 3 days. Then, we sorted GFP-negative
GBM neurosphere cells and put them into soft agar to
examine the changes of tumorigenicity. Medium alone cul-
tured GBM neurospheres were used as a control. We found
that hBMECs promoted clonogenesis of GBM neurospheres
(Fig. 4C). CD133 expression was also induced in GBM neuro-
spheres precultured with hBMECs, indicating CSLC popula-
tion is increased (Fig. 4C). Interestingly, the proliferation rate
of the entire GBM neurosphere culture (detected by prolifera-
tion marker PCNA expression using Western blot and percen-
tage of Ki-67 positive population in the whole culture) did
not change when precultured with hBMECs compared with
Figure 4. NOTCH ligand JAG1 or DLL1 promotes GBM neurosphere growth in vitro. A, soluble ligand JAG1 peptide treatment for 5 days induced growth of
HSR-GBM1 and HSR-GBM2 in a dose-dependent fashion (left and middle). JAG1 or DLL1 peptide also induced growth of HSR-GBM3 (right). B,
2 mg/mL JAG1 peptide treatment increased CD133mRNA expression in HSR-GBM1 (left). A total of 2 mg/mL JAG1 peptide treatment also increased the CD15-
positive CSLC population in GBM neurospheres detected by immunofluorescence (right, n ¼ 6 random fields, *, P < 0.05, t test). C, GBM neurospheres
cocultured with GFP-labeled hBMECs were sorted by flow cytometry and examined clonogenesis by soft agar formation assay. GBM cells formed more
colonies when precultured with hBMECs (n ¼ 6 wells were counted, *, P < 0.01, t test). In addition, expression of CSLC marker CD133 was also
induced at mRNA level in GBM neurospheres precultured with hBMECs compared with those precultured with medium only (right, n ¼ 6 repeats of this
experiment, *, P < 0.01, t test). D, there was no proliferation change in GBM neurospheres precultured with or without hBMECs, identified by PCNA protein
expression using Western blot and percentage of Ki-67 positive population by immunofluorescence. However, CD133 expression was significantly
induced in GBM neurospheres precultured with hBMECs (right). b-Actin was used as a loading control.
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precultured with medium only (Fig. 4D), whereas expression
of CSLC marker CD133 was significantly increased (Fig. 4D).
These data suggest that hBMECs only induce GBM CSLC self-
renewal instead of proliferation of the whole culture (Supple-
mentary Fig. S5). Taken together, these data show that
NOTCH ligand JAG1 and DLL1 are sufficient to promote
GBM CSLC self-renewal in vitro, suggesting that the endothe-
lial or tumor cells that express higher levels of NOTCH ligands
in GBM may provide these ligands to GBM CSLCs to activate
the NOTCH pathway and promote self-renewal of GBM
CSLCs.
Knockdown of NOTCH ligand expression in hBMECs by
shRNA decreases CSLC population in cocultured GBM
neurospheres in vitro
To further investigate whether NOTCH ligands expressed in
endothelial cells are required for GBM CSLC growth, we also
conducted loss-of-ligand function studies in endothelial cells
cocultured with GBM neurospheres. As JAG1 and DLL4 are the
predominantly expressed NOTCH ligands in hBMECs (Fig. 2),
we first knocked down JAG1 expression in hBMECs using
shRNA lentiviral vector pSicoR-shJAG1-GFP (Fig. 5A and B).
Then, shJAG1 or control lentivirus infected hBMECs were
Figure 5.Knocking down JAG1 expression in hBMECs by shRNA decreases CSLC population in coculturedGBMneurospheres in vitro. A, schematic showing
the experimental approach used to examine if NOTCH ligands expressed in endothelial cells are essential for cocultured GBMneurosphere growth. B,Western
blot showed that JAG1 expression was significantly knocked down by shJAG1 lentiviruses in hBMECs to be cocultured with GBM neurospheres.
CD31 was served as an internal control. HSR-GBM1 growth was increased when cocultured with hBMECs compared with neurospheres cultured by medium
only, whereas knockdown of JAG1 expression in hBMECs abrogated hBMEC-induced HSR-GBM1 growth. C, CD15-positive CSLC population detected by
immunofluorescence was also reduced in GBM neurospheres cocultured with shJAG1-infected hBMECs compared with GBM neurospheres cocultured with
empty vector-infected hBMECs. D, knockdown of JAG1 expression in hBMECs decreased CD133-positive population in HSR-GBM1 neurospheres
cocultured with hBMECs compared with HSR-GBM1 neurospheres cultured with empty vector-infected hBMECs (left). mRNA expression of CD133
was also lowered in HSR-GBM1 neurosphere cells cocultured with shJAG1-infected hBMECs compared with HSR-GBM1 cells cocultured with empty vector-
infected hBMECs (middle). There was no proliferation change in HSR-GBM1 neurospheres cocultured with empty vector- or shJAG1-infected hBMECs,
identified by PCNA protein expression using Western blot (right).
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cocultured with GBM neurospheres using serum-free
endothelial cell culture medium for 3 days. GBM neurosphere
cells (GFP-negative) were subsequently sorted by flow cyto-
metry, and tumor growth and the CD133-positive population
were assessed by MTS assay and flow cytometry, respectively
(Fig. 5A). We found that GBM neurosphere growth was
increased when cocultured with hBMECs compared with
neurospheres cultured by medium only, whereas knockdown
JAG1 expression by shRNA in endothelial cells abrogated
hBMEC-induced GBM growth (Fig. 5B). CD15-positive popu-
lation was also reduced in GBM neurospheres cocultured with
shJAG1-infected hBMECs (Fig. 5C). Furthermore, knockdown
of JAG1 expression in hBMECs decreased CD133-positive
population and CD133 mRNA expression in GBM neuro-
spheres cocultured with hBMECs (Fig. 5D). However, GBM
neurosphere proliferation was not changed when cocultured
with shJAG1-infected hBMECs (Fig. 5D). Taken together, these
data showed that reduced CSLCs in GBM neurospheres when
cocultured with shJAG1-infected hBMECs was due to reducing
CSLC self-renewal, but not due to reduced proliferation of the
whole culture (Supplementary Fig. S5), suggesting that
NOTCH ligands expressed in hBMECs are essential for the
maintenance of GBM CSLCs in vitro.
Knocking down JAG1 or DLL4 expression in hBMECs by
shRNA inhibits growth of GBM intracranial xenografts
derived from the mixture of GBM neurosphere cells and
hBMECs
To examine whether expression of NOTCH ligands in
endothelial cells is required for GBM CSLCs growth in vivo,
shJAG1- or shDLL4-infected hBMECs were mixed with GBM
neurosphere cells (ratio 1:10) and injected into the brain of
immunodeficient mice (Fig. 6A). Tumor growth was moni-
tored by MRI and tumor volume calculated (Fig. 6A). We
found that GBM neurospheres cocultured with shJAG1- or
shDLL4-infected hBMECs developed significantly smaller
intracranial xenografts compared with those derived from a
mixture of GBM neurospheres and empty vector-infected
hBMECs (Fig. 6B and C). Furthermore, we examined the cell
specificity of the NOTCH ligand effect by using another type of
human endothelial cells, HUVECs, and found that knockdown
of JAG1 expression in HUVECs also reduced growth of intran-
cranial xenografts (Fig. 6D). These data show that NOTCH
ligands expressed in endothelial cells contribute to the growth
of intracranial xenografts derived from the mixture of GBM
neurosphere cells and endothelial cells, indicating that
endothelial cells may function as a niche for GBM CSLCs
by providing NOTCH ligands to NOTCH receptors expressed
in GBM CSLCs.
CD133-positive population is reduced in GBM
xenografts derived from mixture of GBM neurospheres
and hBMECs with ligand knockdown
To examine the CSLC population changes in GBM xeno-
grafts derived from a mixture of GBM neurosphere and
endothelial cells with or without ligand knockdown, first
we sorted human GBM cells using mouse cell surface antigen
(to remove mouse cells) and GFP (to remove human endothe-
lial cells as they were infected with pSicoR-GFP lentiviral
vector with or without shRNA against NOTCH ligand;
Fig. 6A). Then we examined the CD133-positive GBM cell
changes (Fig. 6A). We found that CD133-positive GBM CSLCs
were significantly reduced in GBM xenografts mixed with
shJAG1 or shDLL4-infected hBMECs (Fig. 7A). Similarly,
CD133-positive population was also decreased in GBM xeno-
grafts mixed with shJAG1-infected HUVECs (Fig. 7A). Con-
sistent with these data, CD15-positive GBM CSLC population
was also reduced in GBM xenografts mixed with shJAG1-
infected hBMECs (Fig. 7A). However, there was no significant
change in tumor proliferation (Fig. 7B) and apoptosis (Fig. 7C)
in the xenografts derived from the mixture of GBM neuro-
spheres and hBMECs with JAG1 or DLL4 knockdown, suggest-
ing that reduced GBM intracranial xenograft growth was due
to loss of CSLCs (Supplementary Fig. S5), which need to
receive NOTCH ligands from endothelial cells to activate
NOTCH for their self-renewal. These data are consistent with
previous findings that the endothelial niche mainly affects
CSLCs instead of the proliferation and apoptosis of the whole
tumor (16). Taken together, our results show that NOTCH
ligands expressed in endothelial cells are critical for the
propagation of GBM CSLCs.
Discussion
In this study, we explored the molecular mechanism under-
lying NOTCH activation in GBM CSLCs. We found that
endothelial cells within the tumor function as a CSLC niche
to promote CSLC self-renewal by providing NOTCH ligands to
the NOTCH receptors expressed in GBM CSLCs (Supplemen-
tary Fig. S6).
To our knowledge, there is still no published documenta-
tion addressing whether cell contact-dependent signaling
pathways contribute to CSLC self-renewal within their niche
in GBM. Here, we first show that NOTCH ligands are expressed
by endothelial cells and some tumor cells around the NESTIN-
and NOTCH receptor-positive CSLCs in primary GBM sam-
ples. Then, we show that knockdown of NOTCH ligand JAG or
DLL in endothelial cells decreases CD133-positive population
in GBM neurospheres in vitro and inhibits cocultured GBM
neurosphere propagation in vivo. Finally, we show that the
reduced GBM xenograft growth is due to decreased GBM
CSLC population. Taken together, our data provide experi-
mental evidence that endothelial cells function as CSLC niche
by providing NOTCH ligands to activate NOTCH signaling in
GBM CSLCs (Supplementary Fig. S6). Therefore, several novel
and innovative approaches can be developed based on inter-
rupting the interaction between CSLCs and their niche(s). For
example, a NOTCH ligand blocking antibody or peptide, in
combination with chemo- and radiation-therapy and CSLC-
targeting therapy, may result in improved GBM treatment.
In the CNS, that endothelial cells can function as a stem cell
niche was initially found in normal NSCs, with endothelial
cells promoting asymmetric self-renewal of NSCs from the
SVZ (15). Later, it was confirmed that the vascular niche
regulates self-renewal of NSCs in vivo (34) at both embryonic
and adult stages (35). In addition, it has been shown that the
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NOTCH signaling pathway plays a critical role in regulating
niche-dependent self-renewal of NSC in SVZ (36, 37). Further-
more, there is some experimental evidence showing that GBM
may originate from SVZNSCs (38). Consistent with the normal
stem cell niche, it has also been shown that endothelial cells
function as a cancer stem cell niche to promote CD133þ CSLC
growth in GBM andmedulloblastoma (16). Here, we show that
the endothelial niche provides NOTCH ligands to GBM CSLCs
to activate NOTCH signaling for their self-renewal. Together,
these data indicate that GBM CSLCs share a common feature
with their normal cognate in not only being endothelial niche
dependent, but also NOTCH pathway dependent.
Although providing NOTCH ligands could be a mechanism
by which endothelial niche maintains GBM CSLCs, the cause
of expression of NOTCH ligands in the endothelial niche in
GBM is still unclear. It has been shown that CD133-positive
GBM CSLCs induce VEGF expression which may contribute to
angiogenesis or endothelial niche formation in GBM (39).
Previous studies have also shown that VEGF induces DLL4
expression in both physiologic and pathologic angiogenesis
Figure 6. Knocking down JAG1 or
DLL4 expression by shRNA in
hBMECs inhibits growth of GBM
intracranial xenografts derived
from the mixture of GBM
neurospheres and hBMECs. A,
schematic showing the
experimental approach used to
examine if NOTCH ligands
expressed in endothelial cells are
essential for the growth of GBM
intracranial xenografts derived
from the mixture of GBM
neurospheres and endothelial
cells. B, MRI showed that the
growth of GBM intracranial
xenografts derived from a mixture
of GBM neurospheres and
shJAG1 infected hBMECs was
much slower than those derived
from a mixture with empty vector
infected hBMECs (n ¼ 10 per
cohort, *, P < 0.01, t test). C, MRI
scanning showed that the growth
of GBM intracranial xenografts
derived from a mixture of GBM
neurospheres and shDLL4
infected hBMECs was much
slower than those derived from a
mixture with empty vector infected
hBMECs (n ¼ 10 per cohort, *, P <
0.05, t test). D, growth of GBM
intracranial xenografts derived
from a mixture of GBM
neurospheres and a second type
of endothelial cells (HUVECs)
infected with shJAG1 was also
significantly slower than those
derived from a mixture with empty
vector infected HUVECs (n¼ 5 per
cohort, *, P < 0.05, t test).
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(40, 41). It is, therefore, possible that expression of NOTCH
ligands in endothelial cells originates from GBM CSLCs
through the VEGF pathway. In addition, endothelial cells
may not be the only source of NOTCH ligands to GBM CSLCs.
Our data show that some primary GBM cells also express
DLL1 and differentiated tumor cells have elevated DLL1
expression compared with GBM neurospheres, indicating that
differentiated tumor cells may also function as niche cells for
Figure 7. CSLC population is
reduced in GBM xenografts
derived from mixture of GBM
neurospheres and hBMECs with
ligand knockdown. A, intracranial
xenografts derived from the
mixture of GBM neurospheres and
hBMECs were dissected and
dissociated into single cell
suspension to examine the
CD133-positive population by
flow cytometry. CD133-positive
population was significantly
decreased in the xenograft from
GBM neurospheres and shJAG1
or shDLL4 infected hBMECs
compared with the xenograft from
GBM neurospheres and vector
infected hBMECs (top). CD133-
positive population was also
significantly decreased in the
xenograft from GBM
neurospheres and shJAG1–
infected HUVECs compared with
the xenograft from GBM
neurosphere and vector-infected
HUVECs (bottom left and middle).
In addition, CD15-positive
population was also significantly
decreased in the xenograft from
GBM neurospheres and shJAG1
infected hBMECs compared with
the xenograft from GBM
neurospheres and vector infected
hBMECs (bottom right). B,
immunofluorescent staining of Ki-
67 in the xenografts derived from
the mixture of GBM neurospheres
and hBMECs with JAG1
knockdown (top) or DLL4
knockdown (bottom) showed no
proliferation changes. C,
immunofluorescent staining of
cleaved caspase 3 in the
xenografts derived from the
mixture of GBM neurospheres and
hBMECs with JAG1 knockdown
(top) or DLL4 knockdown (bottom)
showed no apoptosis changes.
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the maintenance of CSLCs. Further experimental evidence is
needed to address this point.
The endothelial niche maintaining GBM CSLC self-renewal
could be through multiple ways. In this study, we show that
endothelial cells function as a stem cell niche for GBM CSLCs
by directly providing NOTCH ligands. However, a recent study
shows that nitric oxide (NO) released from tumor endothe-
lium diffuses to neighboring glioma stem-like cells and acti-
vates the NOTCH pathway within these stem-like cells in a
PDGF-induced mouse GBM model (42). It is, therefore, pos-
sible that activation of NOTCH signaling in GBM CSLCs
maybe through both NOTCH ligand dependent and indepen-
dent ways. In addition, 2 recent studies report that activation
of HIF2a and PI3K pathway are required for CSLC growth
within the endothelial niche in GBM and medulloblastoma
(43, 44). These data not only further support the hypothesis
that CSLCs share a common feature with their normal cog-
nates in terms of dependence on an endothelial niche, but also
suggest that the interaction between CSLCs and their
endothelial niche could be through multiple mechanisms.
If GBM CSLCs reside within endothelial niche to self-renew,
targeting both CSLC and its niche may be necessary to
eliminate CSLCs. Indeed, inhibition of angiogenesis by VEGF
blocking antibody, bevacizumab, has shown encouraging
results in recurrent GBM patients (45). One possible reason
is that bevacizumab depletes tumor blood vessels and self-
renewing CSLCs in GBM (16). However, given the evidence of
heterogeneity of GBM (46, 47), VEGF resistant GBM cells may
develop. Therefore, targeting endothelial stem cell niche by
NOTCH ligand blocking antibodies may be another alternative
approach to treat GBM patients. Indeed, recent reports show
that DLL4 blocking antibody reduces growth of tumor which
are resistant to VEGF blocking antibody therapy (48–50).
Thus, targeting the NOTCH ligand-dependent endothelial
niche may be a novel way to treat GBM patients, particularly
for those patients who are resistant to VEGF inhibitor therapy.
In summary, we have shown that endothelial cells func-
tion as a CSLC niche by providing NOTCH ligands to CSLCs
for self-renewal. Targeting of CSLCs and stem cell niche via
NOTCH inhibition and NOTCH ligand blockade may provide
an innovative approach for GBM treatment, as niche cells
and the NOTCH signaling pathway are essential for self-
renewal of GBM CSLCs. Although the current study focuses
on GBM, this approach may have relevance to multiple
forms of cancer.
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